Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.82 |
| ▸ | PRMT5 | O14744 | 11/20 | 0.78 |
| ▸ | EGFR | P00533 | 7/20 | 0.76 |
| ▸ | HTR2A | P28223 | 3/20 | 0.73 |
| ▸ | HTR2C | P28335 | 3/20 | 0.73 |
| ▸ | HTR2B | P41595 | 3/20 | 0.73 |
| ▸ | HTR7 | P34969 | 2/20 | 0.71 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.69 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.69 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.69 |
| ▸ | RAD52 | P43351 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | OXTR | P30559 | 1/20 | 0.66 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7488649 | 0.90 | PRMT5 (0.72) | KMT2AMEN1PRMT5EGFRHTR2A | |
| SCHEMBL6779743 | 0.88 | KMT2A (0.68) | KMT2AMEN1PRMT5EGFRHTR2A | |
| SCHEMBL18932890 | 0.86 | HTR2A (0.78) | KMT2AMEN1PRMT5EGFRHTR2A | |
| SCHEMBL1520425 | 0.86 | HTR2C (0.78) | KMT2AMEN1PRMT5EGFRHTR2A | |
| SCHEMBL764810 | 0.85 | HTR2A (1.00) | KMT2AMEN1HTR2AHTR2CHTR2B | |
| SCHEMBL538174 | 0.84 | HTR7 (0.76) | KMT2AMEN1PRMT5EGFRHTR2A | |
| SCHEMBL6782129 | 0.82 | HTR7 (0.82) | KMT2AMEN1PRMT5EGFRHTR2A | |
| SCHEMBL17383997 | 0.82 | HTR2C (0.74) | KMT2AMEN1PRMT5EGFRHTR2A | |
| SCHEMBL8320590 | 0.81 | PRMT5 (0.81) | KMT2AMEN1PRMT5EGFRHTR2A | |
| SCHEMBL6407705 | 0.81 | MEN1 (0.58) | KMT2AMEN1PRMT5EGFRHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | PTC THERAPEUTICS, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| EP-2434891-B9 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200317668-A1 | METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION | PTC THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-3718405-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC Therapeutics, Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-2434891-B1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS INC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20190194188-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| CN-106167488-A | Treatment cancer and the method for non-neoplastic conditions | PTC医疗公司 | 2016-11-30 | — | — | CN | disclosed |
| US-20160340354-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-9351964-B2 | Methods for treating cancer and non-neoplastic conditions | PTC THERAPEUTICS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20120157400-A1 | METHODS FOR TREATING KAPOSI SARCOMA | PTC THERAPEUTICS, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157402-A1 | METHODS FOR TREATING BRAIN TUMORS | PTC THERAPEUTICS, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20050113402-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | SUI ZHIHUA (US) | 2005-05-26 | — | — | US | disclosed |
| US-6818646-B2 | 1,2,3,4-TETRAHYDRO-2-(5-(2-PYRIDINYL)-PYRIMIDIN-2-YL)-3-(2,3 -DIHYDROBENZOFURANYL)-9H-PYRROLO-(3,4-B)QUINOLIN-9-ONE; MALE ERECTILE DYSFUNCTION; SEXUAL DISORDERS | SUI ZHIHUA (US) | 2004-11-16 | — | — | US | disclosed |
| EP-1296981-B1 | SUBSTITUTED PYRROLOPYRIDINONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2004-10-06 | — | — | EP | disclosed |
| US-6720331-B2 | HAVING ANTI-MITOTIC ACTIVITY FOR THERAPY OF CANCER | NATIONAL SUN YAT-SEN UNIVERSITY (TW) | 2004-04-13 | — | — | US | disclosed |
| US-20040044021-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | SUI ZHIHUA (US) | 2004-03-04 | — | — | US | disclosed |
| US-6635638-B2 | Treatment of sexual dysfunction, cardiovascular system disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-10-21 | — | — | US | disclosed |
| US-20030040527-A1 | 1-substituted 1,2,3,4-tetrahydro-beta-carboline and 3,4-dihydro-beta-carboline and analogs as antitumor agents | NATIONAL SUN YAT-SEN UNIVERSITY (TW) | 2003-02-27 | — | — | US | disclosed |
| US-20020010183-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113402-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | PDE5A, PDE3A, PDE3B | KMT2A 3106/4885MEN1 3847/4885PRMT5 77/4885 |
| US-20120157402-A1 | METHODS FOR TREATING BRAIN TUMORS | HDGF, VEGFA, FLT4 | KMT2A 2231/4885MEN1 309/4885PRMT5 2296/4885 |
| US-20030040527-A1 | 1-substituted 1,2,3,4-tetrahydro-beta-carboline and 3,4-dihydro-beta-carboline and analogs as antitumor agents | DCK, CCR1, CCNT1 | KMT2A 1848/4885MEN1 1035/4885PRMT5 3876/4885 |
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | KMT2A 2631/4885MEN1 2704/4885PRMT5 1727/4885 |
| US-20160340354-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | KMT2A 2639/4885MEN1 2681/4885PRMT5 1685/4885 |
| US-20190194188-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | KMT2A 2639/4885MEN1 2681/4885PRMT5 1685/4885 |
| US-20040044021-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | PDE5A, PDE3A, PDE3B | KMT2A 3200/4885MEN1 3647/4885PRMT5 88/4885 |
| US-20200317668-A1 | METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION | SARS1, POLRMT, EIF2AK2 | KMT2A 3745/4885MEN1 4724/4885PRMT5 791/4885 |
| US-20020010183-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | PDE5A, PDE3A, PDE3B | KMT2A 3200/4885MEN1 3647/4885PRMT5 88/4885 |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | SARS1, EIF2AK2, POLRMT | KMT2A 3736/4885MEN1 4541/4885PRMT5 937/4885 |
| US-20120157400-A1 | METHODS FOR TREATING KAPOSI SARCOMA | HDGF, HIF1AN, VEGFA | KMT2A 1446/4885MEN1 3001/4885PRMT5 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.